GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (37)
  • 1
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2009
    In:  Clinical Cancer Research Vol. 15, No. 3 ( 2009-02-01), p. 778-787
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 15, No. 3 ( 2009-02-01), p. 778-787
    Abstract: Purpose: Macrophages play an important role in breast carcinogenesis. The pathways that mediate the macrophage contribution to breast cancer and the heterogeneity that exists within macrophages are incompletely understood. Macrophage colony-stimulating factor 1 (CSF1) is the primary regulator of tissue macrophages. The purpose of this study was to define a novel CSF1 response signature and to evaluate its clinical and biological significance in breast cancer. Experimental Design: We defined the CSF1 response signature by identifying genes overexpressed in tenosynovial giant cell tumor and pigmented villonodular synovitis (tumors composed predominantly of macrophages recruited in response to the overexpression of CSF1) compared with desmoid-type fibromatosis and solitary fibrous tumor. To characterize the CSF1 response signature in breast cancer, we analyzed the expression of CSF1 response signature genes in eight published breast cancer gene expression data sets (n = 982) and did immunohistochemistry and in situ hybridization for CSF1 response genes on a breast cancer tissue microarray (n = 283). Results: In both the gene microarray and tissue microarray analyses, a consistent subset (17-25%) of breast cancers shows the CSF1 response signature. The signature is associated with higher tumor grade, decreased expression of estrogen receptor, decreased expression of progesterone receptor, and increased TP53 mutations (P & lt; 0.001). Conclusions: Our data show that the CSF1 response signature is consistently seen in a subset of breast carcinomas and correlates with biological features of the tumor. Our findings provide insight into macrophage biology and may facilitate the development of personalized therapy for patients most likely to benefit from CSF1-targeted treatments.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2009
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 19, No. 10_Supplement ( 2010-10-01), p. B11-B11
    Abstract: As health disparities in general and cancer health disparities specifically affect underserved and minority populations disproportionately, the training of racially, ethnically and culturally concordant scientists and researchers may help to address these issues. Funded under the American Recovery and Reconciliation Act of 2009 (3P20CA138017-01S1) and the National Cancer Institute's rubric “Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership,” the Lincoln University-Fox Chase Partnership in Cancer Research and Training established its summer internship program. The overall purpose of the collaborative summer internship was to create a paid, 10-week long research and training opportunity for selected undergraduate students from a Historically Black College/University to train at Fox Chase Cancer Center located in Philadelphia, Pennsylvania. The summer internship is designed to train a cadre of Lincoln students capable of conducting first-class biomedical and population-based research and augment the number of capable researchers available to reduce the problem of cancer health disparities. The research and training program utilized a community-based participatory research approach. Students were informed of the internship via events at Fox Chase, in class announcements, brochures and word-of-mouth. A Research Training Committee was established. The partners developed a formalized recruitment and selection process. Selected students were partnered with and co-mentored by one Lincoln faculty and one Fox Chase faculty. A comprehensive orientation and training was developed. Evaluations assessed students’ knowledge and experiences. Debriefings were also held with mentors to gain insight into their observations and experiences. For two consecutive years, four students have been selected each year, co-mentored by Lincoln and Fox Chase faculty. A comprehensive orientation and training program was developed and administered in sections at both institutions covering a myriad of topics in cancer, cancer research, research and the sciences. Surveys were administered to the students evaluating both their knowledge and the students’ perceptions of the program itself. With the guidance and supervision of their faculty co-mentors, students developed and carried out their 10-week long research projects. Midway through their program, all of the students presented their research to-date at the partnership's External Advisory Board meeting, where they received constructive critiques of their research and presentations. At the conclusion of the 2009 internship, three students won prizes for their research posters. Since the inception of the program, two interns have been hired at Fox Chase. The collaborative co-mentoring by faculty was instrumental in providing the students with balance and support, both scientifically and academically. We found improvement in students’ knowledge of and proficiency in conducting research in general and cancer research specifically. With the appropriate training and encouragement, students from racially, ethnically and culturally diverse backgrounds can find success in pursuing careers in science and research, while working to reduce cancer health disparities. Citation Information: Cancer Epidemiol Biomarkers Prev 2010;19(10 Suppl):B11.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 21, No. 15 ( 2015-08-01), p. 3501-3511
    Abstract: Purpose: Leiomyosarcoma is a malignant neoplasm with smooth muscle differentiation. Little is known about its molecular heterogeneity and no targeted therapy currently exists for leiomyosarcoma. Recognition of different molecular subtypes is necessary to evaluate novel therapeutic options. In a previous study on 51 leiomyosarcomas, we identified three molecular subtypes in leiomyosarcoma. The current study was performed to determine whether the existence of these subtypes could be confirmed in independent cohorts. Experimental Design: Ninety-nine cases of leiomyosarcoma were expression profiled with 3′end RNA-Sequencing (3SEQ). Consensus clustering was conducted to determine the optimal number of subtypes. Results: We identified 3 leiomyosarcoma molecular subtypes and confirmed this finding by analyzing publically available data on 82 leiomyosarcoma from The Cancer Genome Atlas (TCGA). We identified two new formalin-fixed, paraffin-embedded tissue-compatible diagnostic immunohistochemical markers; LMOD1 for subtype I leiomyosarcoma and ARL4C for subtype II leiomyosarcoma. A leiomyosarcoma tissue microarray with known clinical outcome was used to show that subtype I leiomyosarcoma is associated with good outcome in extrauterine leiomyosarcoma while subtype II leiomyosarcoma is associated with poor prognosis in both uterine and extrauterine leiomyosarcoma. The leiomyosarcoma subtypes showed significant differences in expression levels for genes for which novel targeted therapies are being developed, suggesting that leiomyosarcoma subtypes may respond differentially to these targeted therapies. Conclusions: We confirm the existence of 3 molecular subtypes in leiomyosarcoma using two independent datasets and show that the different molecular subtypes are associated with distinct clinical outcomes. The findings offer an opportunity for treating leiomyosarcoma in a subtype-specific targeted approach. Clin Cancer Res; 21(15); 3501–11. ©2015 AACR.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2008
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 17, No. 10 ( 2008-10-01), p. 2865-2871
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 17, No. 10 ( 2008-10-01), p. 2865-2871
    Abstract: Objective: We sought to evaluate the performance of the human papillomavirus high-risk DNA test in patients 30 years and older. Materials and Methods: Screening (n = 835) and diagnosis (n = 518) groups were defined based on prior Papanicolaou smear results as part of a clinical trial for cervical cancer detection. We compared the Hybrid Capture II (HCII) test result with the worst histologic report. We used cervical intraepithelial neoplasia (CIN) 2/3 or worse as the reference of disease. We calculated sensitivities, specificities, positive and negative likelihood ratios (LR+ and LR−), receiver operating characteristic (ROC) curves, and areas under the ROC curves for the HCII test. We also considered alternative strategies, including Papanicolaou smear, a combination of Papanicolaou smear and the HCII test, a sequence of Papanicolaou smear followed by the HCII test, and a sequence of the HCII test followed by Papanicolaou smear. Results: For the screening group, the sensitivity was 0.69 and the specificity was 0.93; the area under the ROC curve was 0.81. The LR+ and LR− were 10.24 and 0.34, respectively. For the diagnosis group, the sensitivity was 0.88 and the specificity was 0.78; the area under the ROC curve was 0.83. The LR+ and LR− were 4.06 and 0.14, respectively. Sequential testing showed little or no improvement over the combination testing. Conclusions: The HCII test in the screening group had a greater LR+ for the detection of CIN 2/3 or worse. HCII testing may be an additional screening tool for cervical cancer in women 30 years and older. (Cancer Epidemiol Biomarkers Prev 2008;17(10):2865–71)
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2008
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2010
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 19, No. 10_Supplement ( 2010-10-01), p. B7-B7
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 19, No. 10_Supplement ( 2010-10-01), p. B7-B7
    Abstract: Interinstitutional partnerships between cancer centers and minority serving, academic institutions provide opportunities to collaboratively and creatively address cancer health disparities. Key was defining the community leadership role of the academic institution. Cancer centers are uniquely equipped to understand the needs of patients by way of basic, population and clinical sciences along with best practices in cancer. Conversely, community-based, minority serving, academic institutions have a distinct ability to educate and train the scientists and researchers of the future, who can provide a culturally sensitive perspective. Under the National Cancer Institute's (NCI) rubric “Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership (MI/CCP),” Fox Chase Cancer Center and Lincoln University embarked on a partnership of “working and learning together.” The partnership is designed to train Lincoln students and faculty capable of conducting first-class biomedical and population-based research and to implement joint research projects that attack cancer health disparities. A secondary objective is to develop collaborative research projects enhancing Lincoln faculty's ability to pursue NIH funding to support discrete, specified, circumscribed projects in areas representing their specific interests and competencies. The partnership utilized a community-based participatory research approach. Governance was established, a project manager was hired and committees were formed to facilitate the activities of the partnership. A collaborative grant was submitted by both institutions. Presidents and senior leadership from both institutions were committed and provided in-kind support for staffing and videoconferencing equipment. Forums for interdisciplinary and interactive teaching, learning and networking were provided for faculty, staff and students of both institutions as well as the community at large. After a short planning period, a governance process was established and the grant was awarded. A10-week long summer internship program was developed for which 4 Lincoln students and 4 faculty mentors were selected annually. Three of the first four interns won awards for their research posters. Two interns were hired by Fox Chase. Two relevant academic courses were added to the Lincoln curriculum. Two joint faculty research projects were selected after a pilot competition. Fox Chase faculty provided several informative lectures at Lincoln. Other community partners were engaged. A memorandum of understanding was established with a third community-based organization further enhancing the P20 partnership. The academic partnership has far exceeded its original expectations. The two institutions as well as other community members continue to work collaboratively to enhance the research and training objectives of the partnership. Not only have the Lincoln University faculty and students been educated in cancer research and training, but additionally the Fox Chase faculty, staff and students have been educated in the benefits and challenges of partnering with a community-based, academic institution. The collaboration continues to evolve and grow in both planned and unplanned directions. Citation Information: Cancer Epidemiol Biomarkers Prev 2010;19(10 Suppl):B7.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 20, No. 10_Supplement ( 2011-09-01), p. B5-B5
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 20, No. 10_Supplement ( 2011-09-01), p. B5-B5
    Abstract: Background: The Region Five GMaP/BMaP Network is a regional partnership representing 18 NCI funded institutions charged with the development and implementation of a comprehensive needs assessment (CNAT). The goal of the principle investigator (PI) component of the CNAT was to capture in-depth PI opinion on necessary elements to successful health disparities research, barriers to success and required funding and infrastructure elements needed to alleviate those barriers. In addition, we hoped to obtain specific recommendations for our network's development to foster successful research collaborations amongst our many institutions and the diverse populations we serve. Methods: The CNAT consisted of a mixed methods approach utilizing four instruments: A principal Investigator Survey and PI Interview and a Biospecimen Facility Survey and Interview. This presentation focuses on preliminary findings from the PI Survey. The surveys were conducted online by PI's during the months of March and April 2011. Qualitative interviews will be conducted between July and August 2011. The PI survey consisted of 48 distinct questions, with affiliated subset questions that covered seven core areas: cancer health disparities research/community, minority biospecimens collection, clinical trials recruitment and retention, bioinformatics/advanced & emerging technology, training, visioning the future; and network analysis. Results: PI online survey was completed by 14 of 18 region five institutions, a 77.8% completion rate. Preliminary findings show our region's investigator expertise is in the areas of CBPR, working with community based organizations, and training CHD researchers, with 84% (11/13) reporting collaborations with institutions and community partners. Most of the populations focused on among the PI's mirrors the populations in institution service areas. Forty-six percent (6/13) of institutions reported having implemented outreach or education strategies in the community to promote biospecimens research, while 69.2% (9/13) reported projects with the aim to improve accrual of minority patients into clinical trials. Four PI's focus 50–100% of their GMaP effort on health disparities programs; while five PI's focus between 50–100% of their GMaP group effort on health disparities research. 84% of PI's collaborate with others to conduct CHD research and community outreach. The most popular areas of CHD research are barriers to cancer screening, health literacy, and cancer (breast, prostate, cervical, and lung). Conclusions: Region Five has significant experience conducting community-based research and community education programs to increase minority/medically underserved population's participation in research. There are opportunities for collaboration among principal investigators and biospecimen facilities around minority biospecimen collection efforts. Region Five has established a formal network called the Cancer Disparities Research Network (CDRN) and is establishing a network website. A result of this preliminary network is the continuation of the collaboration and identification of potential health disparities projects. We anticipate implementing Cancer 102 education and training on research participation, biospecimen donation/biobanking and genetics across our institutions. Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):B5.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 464-464
    Abstract: Morphological features of cancer cell nuclei are linked to gene expression signatures and genomic alterations. In addition, pathologists have leveraged nuclear morphology as diagnostic and prognostic markers. To enable the use of nuclear morphology in digital pathology, we developed a pan-tissue, deep-learning-based digital pathology pipeline for exhaustive nucleus detection, instance segmentation, and classification. We collected & gt; 29,000 manual nucleus annotations from hematoxylin and eosin (H & E)-stained pathology images from 21 tumor types at 40x and 20x magnification from The Cancer Genome Atlas (TCGA) project, as well as a proprietary set of H & E-stained tissue biopsies of skin, liver non-alcoholic steatohepatitis (NASH), colon inflammatory bowel disease (IBD), and kidney lupus. Annotations were used to train an object detection and segmentation model for identifying nuclei. Application of the model to held-out test data, including held-out tissue types, demonstrated performance comparable to state-of-the-art models described in the literature (mean Dice score = 0.80, aggregated Jaccard index = 0.60). We deployed our model to segment nuclei in H & E slides from the breast cancer (BRCA, N = 941) and prostate adenocarcinoma (PRAD, N = 457) TCGA cohorts. We extracted interpretable features describing the shape (circularity, eccentricity), size, staining intensity (mean and standard deviation), and texture of each nucleus. Nuclei were assigned as cancer or other cell types using separately trained convolutional neural networks for BRCA and PRAD. We used the mean and standard deviation of each feature sampled from a random subset of cancer nuclei to summarize the nuclear morphology on each slide (mean (range) = 10,068 (5,981-10,452) cancer cells from each BRCA slide; mean (range) = 10,053 (5,029-10,495) cancer cells from each PRAD slide). We used nuclear features to construct random forest classification models for predicting markers of genomic instability and prognosis: whole-genome doubling (WGD) and homologous recombination deficiency (HRD) status separately in BRCA and PRAD, HER2 subtype in BRCA, and Gleason grade in PRAD. Nuclear features were predictive of WGD (area under the receiver operating characteristic curve (AUROC) = 0.78 BRCA, = 0.69 PRAD) and binarized HRD status (AUROC = 0.65 BRCA, = 0.68 PRAD) on held-out test sets. Nuclear features were predictive of HER2-enriched breast cancer vs. other molecular subtypes (AUROC = 0.72), and distinguished between low risk (6) and moderate/high risk (7-10) Gleason grade in PRAD (AUROC = 0.72). In summary, we present a powerful pan-tissue approach for nucleus segmentation and featurization, which enables the construction of predictive models and the identification of features linking nuclear morphology with clinically-relevant prognostic biomarkers across multiple cancer types. Citation Format: John Abel, Suyog Jain, Deepta Rajan, Ken Leidal, Harshith Padigela, Aaditya Prakash, Jake Conway, Michael Nercessian, Christian Kirkup, Robert Egger, Ben Trotter, Andrew Beck, Ilan Wapinski, Michael G. Drage, Limin Yu, Amaro Taylor-Weiner. AI-powered segmentation and analysis of nuclei morphology predicts genomic and clinical markers in multiple cancer types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 464.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 17, No. 3 ( 2011-02-01), p. 437-446
    Abstract: Purpose: We recently described two types of stromal response in breast cancer derived from gene expression studies of tenosynovial giant cell tumors and fibromatosis. The purpose of this study is to elucidate the basis of this stromal response—whether they are elicited by individual tumors or whether they represent an endogenous host reaction produced by the patient. Experimental Design: Stromal signatures from patients with synchronous dual primaries were analyzed by immunohistochemistry on a tissue microarray (n = 26 pairs) to evaluate the similarity of stromal responses in different tumors within the same patient. We also characterized the extent to which the stromal signatures were conserved between stromal response to injury compared to the stromal response to carcinoma using gene expression profiling and tissue microarray immunohistochemistry. Results: The two stromal response signatures showed divergent associations in synchronous primaries: the DTF fibroblast response is more likely to be similar in a patient with multiple breast primaries (permutation analysis P = 0.0027), whereas CSF1 macrophage response shows no significant concordance in separate tumors within a given patient. The DTF fibroblast signature showed more concordance across normal, cancer, and biopsy site samples from within a patient, than across normal, cancer, and biopsy site samples from a random group of patients, whereas the CSF1 macrophage response did not. Conclusions: The results suggest that the DTF fibroblast response is host-specific, whereas the CSF1 response may be tumor-elicited. Our findings provide further insight into stromal response and may facilitate the development of therapeutic strategies to target particular stromal subtypes. Clin Cancer Res; 17(3); 437–46. ©2010 AACR.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 20, No. 10_Supplement ( 2011-09-01), p. B6-B6
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 20, No. 10_Supplement ( 2011-09-01), p. B6-B6
    Abstract: Objective: The Region Five GMaP/BMaP Network is a regional partnership representing 18 NCI funded institutions charged with the implementation of a comprehensive needs assessment (CNAT). This presentation focuses on preliminary findings from the Biospecimen Facility Survey. Methods: The CNAT consisted of a mixed methods approach utilizing four instruments: A principal Investigator Survey and PI Interview and a Biospecimen Facility Survey and Interview. The surveys were conducted online during the months of March/ April 2011. Interviews will be conducted in July. The goal of the biospecimen facility survey which is the focus of this abstract is to assess minority biospecimen collection, biobanking practices, education, and outreach initiatives. The biospecimen survey consisted of 14 distinct questions, with affiliated subset questions, across five areas. These questions captured details from the institutions’ core facilities and inventory human specimens that were available for research. The survey was completed online by 10 biospecimen facility administrators. Results: Preliminary findings consistently reported disparities in biospecimen collection among minority populations. Eight out of ten facilities reported the types of cancer and racial and ethnic groups from whom they collected specimens. Upon close review of the data, gaps in specimens collected for populations with a high burden of cancer were commonly identified. Seven facilities reported having collected specimen from 116,417 White patients vs. 12,592 Non-White (minority) patients’ and 1648 Hispanic patients’. Tissue (diseased and healthy) was most commonly collected and bodily fluids were least commonly collected. While 40% of the biospecimen facilities have collaborated on biospecimen education efforts, we have learned that 60% of these facilities have collaborated on projects that collect specimens for the study of health disparities. The data mirrors similar findings from the PI survey; over half of our PIs are involved in biospecimen education and minority collection efforts. In reference to bioinformatics and electronic data systems we found that 100% of the Region Five facilities currently use electronic annotation systems for biospecimen collection. However, there is a wide range of data systems/platforms used across the institutions which raise issues of compatibility. Along with this, we have found that 94% of specimens collected by our facilities have associated pathology data available. Biospecimen facility administrators identified barriers which limit them from collaborating in collection programs. However, they also indicated a high desire to collaborate. Conclusions: There is a need to focus on minority biospecimen collection efforts and address the gaps in how race and ethnicity and subtypes of biospecimens are collected across our institutions. Region Five is exploring ways to share instruments and methodologies used to collect race and ethnicity and develop strategies to standardize patient information collected. We anticipate implementing Cancer 101 and 102 education and training on research participation, biospecimen donation/biobanking and genetics across our institutions. In addition, there are opportunities for collaboration among principal investigators and biospecimen facilities around minority specimen collection efforts. Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):B6.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 12, No. 11_Supplement ( 2013-11-01), p. B129-B129
    Abstract: Men with localized prostate cancer vary widely in clinical outcome, with a 30-50% failure rate after primary treatment. There is thus significant interest in developing genomically refined prognostic groups. We sought to evaluate the extent of genetic heterogeneity, both between patients (inter-prostate) and within individual prostate glands (intra-prostate) to assess the impact of genetic heterogeneity on risk stratification within a tight clinical cohort. Copy number aberrations (CNAs) from 75 Gleason 7 patients were determined by OncoScan SNP microarrays. We measure the percentage of genome involved in a CNA, termed percent genome aberration (PGA), a proxy for genomic instability. Additionally, whole genome sequencing was applied to 10 intermediate-risk prostate tumours and matched blood, including multiple manually macro-dissected regions from 5 of the prostates (range 2 to 9). Somatic single nucleotide variants (SNVs) and genomic rearrangements (GR) were extracted from each patient. We find a high degree of inter-prostatic heterogeneity between the 75 Gleason 7 patients, with the number of CNAs per patient ranging from 0 to 929, corresponding to PGA 0 to 16.7%. Known prognostic markers can differentiate between patients at higher risk for biochemical recurrence, but only account for a fraction of the cohort. Notably, when these prognostic genes are examined within multiple regions of five independent tumours, they differ in copy number between cancerous regions of the same prostate. For example, TP53 is deleted in 1/2, 1/3, 4/9, 0/4, and 4/5 prostate regions. Indeed, phylogenetic analysis of geographically distinct regions revealed multi-clonal disease in two of the five patients; separate analyses based on SNVs, CNAs, and GRs all concluded that these patient have two genetically distinct cancers within their prostate. We demonstrate dramatic levels of inter- and intra- prostate genetic heterogeneity within pathologically identical or similar cancers. The observed intra-prostatic genomic heterogeneity, both in terms of multi-focal and multi-clonal disease, has critical implications for clinical management. Prognostic information obtained by biopsy may be inconsistent depending on the site of biopsy, and applying personalized medicine to prostate cancer will be challenging. This study highlights the need for further evaluation of how intra-prostatic heterogeneity is related to patient prognosis. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B129. Citation Format: Emilie Lalonde, Paul C. Boutros, Michael Fraser, Richard de Borja, Nicholas J. Harding, Dominique Trudel, Alice Meng, Pablo H. Hennings-Yeomans, Andrew McPherson, Amin Zia, Jianxin Wang, Timothy Beck, Natalie S. Fox, Taryne Chong, Michelle Sam, Jeremy Johns, Lee Timms, Nicholas Buchner, Sohrab Shah, Cenk Sahinalp, Thomas J. Hudson, John D. McPherson, Theodorus van der Kwast, Robert G. Bristow. Clinical implications of inter- and intra- prostatic heterogeneity. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B129.
    Type of Medium: Online Resource
    ISSN: 1535-7163 , 1538-8514
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2062135-8
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...